Modifications to CHROMagar Acinetobacter for improved selective growth of multi-drug resistant Acinetobacter
1Centre for Immunology and Infectious Disease, Blizard Institute of Cell and Molecular Science, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. d.w.wareham@qmul.ac.uk
Journal of Clinical Pathology
|December 7, 2010
Summary
CHROMagar Acinetobacter effectively isolates Acinetobacter baumannii, suppressing other bacteria. With KPC supplement, it specifically identifies carbapenem-resistant strains, aiding in targeted antimicrobial therapy.
Area of Science:
- Clinical microbiology
- Antimicrobial resistance
Background:
- Acinetobacter baumannii is a significant opportunistic pathogen.
- Carbapenem resistance in A. baumannii poses a major treatment challenge.
Purpose of the Study:
- To evaluate the performance of CHROMagar Acinetobacter for selective isolation and identification of Acinetobacter baumannii.
- To assess the utility of a KPC supplement for detecting carbapenem-resistant A. baumannii.
Main Methods:
- Performance evaluation of CHROMagar Acinetobacter medium.
- Assessment of selective growth suppression of Gram-positive and Gram-negative species.
- Evaluation of KPC supplement for selective growth of carbapenem-resistant strains.
Main Results:
- CHROMagar Acinetobacter demonstrated effective suppression of non-target Gram-positive and Gram-negative bacteria.
- The addition of KPC supplement allowed for the specific growth of carbapenem-resistant Acinetobacter baumannii.
Conclusions:
- CHROMagar Acinetobacter is a valuable tool for the selective isolation of A. baumannii.
- The KPC-supplemented medium facilitates the identification of carbapenem-resistant A. baumannii, aiding in infection control and treatment strategies.
Related Concept Videos
00:57Antibiotic Selection
Overview
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...